| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Hematology, Oncology, and Transfusion Medicine (Drs. Gleissner, Siehl, Korfel, and Thiel), University Hospital Benjamin Franklin, Free University of Berlin; and Department Molecular Genetics (Dr. Reinhardt), Max Planck Institute Berlin, Germany.
Address correspondence and reprint requests to Dr. B. Gleissner, Department of Haematology, Oncology and Transfusion Medicine, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany; e-mail: gleisner{at}zedat.fu-berlin.de
Background: Cytologic evaluation of CSF does not consistently detect malignant cells in patients with primary CNS lymphoma (PCNSL). The potentially more sensitive molecular assessment of monoclonality has not been shown in CSF samples.
Methods: The authors studied nested PCR of the complementary determining region III (CDR III) on 76 CSF specimens of patients with PCNSL. Patients with systemic disseminated B-cell non-Hodgkin’s lymphoma (n = 17) and 17 patients with no history of lymphoma were compared. PCR products were evaluated by automated fluorescent fragment analysis (ALF).
Results: In 68 patients with PCNSL, the authors analyzed the first obtained CSF sample. Nevertheless, 60 patients were taking corticosteroids. In 16 PCNSL samples, amplifiable DNA was not yielded. Taking into account that at least two independent assays have to be performed, CDR III PCR consistently revealed monoclonal products in eight PCNSL and polyclonal results in 52 PCNSL specimens. CDR III PCR detected no monoclonal PCR products in patients without history of lymphoma. In 10 patients with PCNSL, the PCR result and the CSF cytology were discordant. Concerning therapeutic impact, leptomeningeal tumor spread did not predict tumor response in this group of patients with PCNSL.
Conclusions: This study performed CDR III PCR as a routine diagnostic technique applicable even on CSF samples with low cell counts. These data present low incidence of leptomeningeal involvement in this subset of pretreated PCNSL patients. Because the CSF evaluation did not predict outcome in our patients, further analysis in patients with PCNSL should focus on CSF samples that are obtained very early after diagnosis.
This article has been cited by other articles:
|
|
 |
|
  F. H. Hochberg, F. J. Rodriguez, J.L.D. Atkinson, E. G. Shaw, B. M. Keegan, and O. H. Kantarci A 54-year-old woman with progressive gait disturbance and MRI abnormalities Neurology, August 11, 2009; 73(6): 466 - 474. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schlegel Review: Primary CNS lymphoma Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104. [Abstract] [PDF]
|
|
|
|
|
|
L. Fischer, P. Martus, M. Weller, H. A. Klasen, B. Rohden, A. Roth, B. Storek, M. Hummel, T. Nagele, E. Thiel, et al. Meningeal dissemination in primary CNS lymphoma: Prospective evaluation of 282 patients Neurology, September 30, 2008; 71(14): 1102 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.L. Davies, R. Chinn, M. Nelson, M. Rasanesan, B. Gazzard, T. Powles, M. Bower, and J. Stebbing Outcome in AIDS-Related Systemic Non-Hodgkin Lymphoma and Leptomeningeal Disease Is Not Predicted by a CT Brain Scan AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1988 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kiewe, C. Loddenkemper, I. Anagnostopoulos, M. Reinwald, E. Thiel, and A. Korfel High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma Neuro-oncol, April 1, 2007; 9(2): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. DeAngelis and J. G. Cairncross A better way to find tumor in the CSF? Neurology, February 12, 2002; 58(3): 339 - 340. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
